The role of p21waf1/cip1 and p27Kip1 in HDACi-mediated tumor cell death and cell cycle arrest in the Eμ-myc model of B-cell lymphoma

Oncogene

Volumn 33, Issue 47, 2014, Pages 5415-5423

  Newbold, A ^a   Salmon, J M ^a   Martin, B P ^a   Stanley, K ^a   Johnstone, R W ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

CDKN1A; cell cycle arrest; histone deacetylase inhibitors; tumor suppressor protein

Indexed keywords

CDKN1A PROTEIN, MOUSE; CDKN1B PROTEIN, MOUSE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; VORINOSTAT;

ANIMAL; APOPTOSIS; CELL CYCLE CHECKPOINT; CELL DEATH; DISEASE MODEL; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; LYMPHOMA, B-CELL; MALE; METABOLISM; ONCOGENE MYC; PATHOLOGY; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL DEATH; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; GENES, TUMOR SUPPRESSOR; HISTONE DEACETYLASE INHIBITORS; HYDROXAMIC ACIDS; LYMPHOMA, B-CELL; MALE; MICE, KNOCKOUT; MICE, TRANSGENIC;

EID: 84888375767     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.482     Document Type: Article

References (27)

1. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769-784.
2. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002; 1: 287-299.
3. Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 2001; 98: 10833-10838.
4. Lindemann RK, Newbold A, Whitecross KF, Cluse LA, Frew AJ, Ellis L et al. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci USA 2007; 104: 8071-8076.
5. Newbold A, Lindemann RK, Cluse LA, Whitecross KF, Dear AE, Johnstone RW. Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin. Mol Cancer Ther 2008; 7: 1066-1079.
6. Ellis L, Bots M, Lindemann RK, Bolden JE, Newbold A, Cluse LA et al. The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy. Blood 2009; 114: 380-393.
7. Burgess AJ, Pavey S, Warrener R, Hunter LJ, Piva TJ, Musgrove EA et al. Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. Mol Pharmacol 2001; 60: 828-837.
8. Ocker M, Schneider-Stock R. Histone deacetylase inhibitors: signalling towards p21cip1/waf1. Int J Biochem Cell Biol 2007; 39: 1367-1374.
9. Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A et al. p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 1995; 9: 650-662.
10. Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 1998; 396: 177-180.
11. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009; 9: 400-414.
12. Martin-Caballero J, Flores JM, Garcia-Palencia P, Serrano M. Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. Cancer Res 2001; 61: 6234-6238.
13. Missero C, Di Cunto F, Kiyokawa H, Koff A, Dotto GP. The absence of p21Cip1/ WAF1 alters keratinocyte growth and differentiation and promotes ras-tumor progression. Genes Dev 1996; 10: 3065-3075.
14. Martins CP, Berns A. Loss of p27(Kip1) but not p21(Cip1) decreases survival and synergizes with MYC in murine lymphomagenesis. Embo J 2002; 21: 3739-3748.
15. Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Ngo L et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci USA 1996; 93: 5705-5708.
16. Archer SY, Meng S, Shei A, Hodin RA. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci USA 1998; 95: 6791-6796.
17. Hitomi T, Matsuzaki Y, Yokota T, Takaoka Y, Sakai T. p15(INK4b) in HDAC inhibitorinduced growth arrest. FEBS Lett 2003; 554: 347-350.
18. Harris AW, Pinkert CA, Crawford M, Langdon WY, Brinster RL, Adams JM. The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. J Exp Med 1988; 167: 353-371.
19. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 2000; 97: 10014-10019.
20. Kramer OH, Knauer SK, Zimmermann D, Stauber RH, Heinzel T. Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis. Oncogene 2008; 27: 732-740.
21. Rosato RR, Almenara JA, Yu C, Grant S. Evidence of a functional role for p21WAF1/ CIP1 down-regulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridol. Mol Pharmacol 2004; 65: 571-581
22. Svechnikova I, Ammerpohl O, Ekstrom TJ. p21waf1/Cip1 partially mediates apoptosis in hepatocellular carcinoma cells. Biochem Biophys Res Commun 2007; 354: 466-471.
23. Pitts TM, Morrow M, Kaufman SA, Tentler JJ, Eckhardt SG. Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models. Mol Cancer Ther 2009; 8: 342-349.
24. Newbold A, Matthews GM, Bots M, Cluse L, Clarke CJP, Banks K-M et al. Molecular and biological analysis of histone deacetylase inhibitors with diverse specificities. Mol Cancer Ther 2013, In Press.
25. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 1999; 13: 2658-2669.
26. Uehara N, Yoshizawa K, Tsubura A. Vorinostat enhances protein stability of p27 and p21 through negative regulation of Skp2 and Cks1 in human breast cancer cells. Oncol Rep 2012; 28: 105-110.
27. Peart MJ, Tainton KM, Ruefli AA, Dear AE, Sedelies KA, O'Reilly LA et al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 2003; 63: 4460-4471.